Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral cediranib for patients with advanced malignancies
Year: 2009
Type: conference-abstract
Source: Journal of Clinical Oncology
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: circulating tumor cells, circulating endothelial cells, bevacizumab, cediranib, VEGFR inhibition, pharmacodynamic biomarkers, VEGFR2 phosphorylation, ERK1/2 phosphorylation, apoptosis, CD105, CD31, advanced cancer, dose escalation, treatment response prediction, laser scanning cytometry, CellSearch
Open Access status: closed
OpenAlex ID: W2249059299
